4th Annual Glomerular Disease Symposium

The 4th Annual Washington University Glomerular Disease Symposium is planned and implemented by physicians from the Division of Nephrology and the Division of Anatomic and Molecular Pathology. This live, in-person course is designed primarily for practicing nephrologists and nephrology trainees, and may also be of interest to rheumatologists, internal medicine physicians and trainees, advanced practice providers, and nephrology nurses.

This 16-hour program provides a comprehensive update on the latest advances in the pathogenesis, diagnosis, and treatment of glomerular diseases. The format includes lectures, panel discussions, interactive breakout workshops, and Q&A sessions to promote active learning. The goal of this activity is to enhance knowledge, skillsstrategy, performance, and patient care.

1. Evaluate and apply current evidencebased diagnostic and therapeutic approaches across major glomerular diseases (e.g., IgA nephropathy, lupus nephritis, ANCAassociated GN, podocytopathies, complementmediated disease, and onconephrology cases) to optimize patient management.
2. Differentiate diseasespecific treatment strategies by interpreting clinical trial data, guideline updates, and expert panel recommendations to support individualized, precisionbased care decisions in glomerular disease.
3. Integrate multidisciplinary insights (nephrology, pathology, genetics, and emerging therapeutics) to improve diagnostic accuracy and selection of targeted therapies in complex glomerular disease presentations.
4. Critically analyze evolving controversies in glomerular disease management (e.g., immunosuppression intensity, timing of intervention, use of plasma exchange, and genetic testing) and apply structured clinical reasoning to realworld patient cases.

American Medical Association (AMA)
Washington University School of Medicine in St. Louis designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The cancellation cut-off dates and fees are specific to each course. Refer to the cancellation policy on the individual course page. Please send cancellation requests to [email protected].

WashU Medicine CME reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred, such as non-refundable airline tickets or hotel penalties.

This meeting is conducted in accordance with the requirements of the Americans with Disabilities Act (ADA) and applicable regulations.
Individuals who require accommodations to participate are encouraged to submit a written request as early as possible, but no later than ten (10) business days prior to the seminar date, to allow sufficient time to arrange appropriate accommodations. Requests received after this deadline will be reviewed and a good faith effort will be made to provide reasonable accommodations to the extent feasible.

Washington University School of Medicine in St. Louis School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Washington University School of Medicine in St. Louis adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including Faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Tingting Li, MD, MSCI, MSCI, FASN
Professor of Medicine
Washington University in St. Louis
St. Louis, MO

Course Director, Faculty

Grant or research support-Alpine Immune Sciences Inc|Grant or research support-Calliditas Therapeutics|Grant or research support-Dimerix|Grant or research support-ENYO Pharma|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Vertex Pharmaceuticals Inc|Other relevant financial or material interests-Amgen (*)|Other relevant financial or material interests-Calliditas Therapeutics (*)|Other relevant financial or material interests-Curio Science, LLC (*)|Other relevant financial or material interests-GlaxoSmithKline/GSK|Other relevant financial or material interests-Novartis (*)|Other relevant financial or material interests-Travere Therapeutics Inc (*)|Other relevant financial or material interests-Vera Therapeutics (*)

Jonathan Barratt, PhD
University of Leicester
Leicester, United Kingdom

Faculty

Duvuru Geetha, MD
Professor of Clinical Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Faculty

Raymond K Hsu, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, CA

Faculty

Anuja Java, MD, MD
Associate Professor of Medicine
Washington University
St. Louis, MO

Faculty

Grant or research support-Novartis Institutes for Biomedical Research/NIBR|Other relevant financial or material interests-Alexion Pharmaceuticals Inc|Other relevant financial or material interests-Apellis Pharmaceuticals, Inc.|Other relevant financial or material interests-Novartis Pharmaceuticals Corporation|Other relevant financial or material interests-Alexion Pharmaceuticals Inc (*)|Other relevant financial or material interests-Apellis Pharmaceuticals, Inc. (*)

Alfred H Kim, MD, PhD, FACR
Associate Professor
Washington University School of Medicine
Saint Louis, MO

Faculty

Consulting Fee-ABBVIE (Relationship has ended)|Consulting Fee-AMGEN (Any division) (Relationship has ended)|Grant or research support-AstraZeneca (Any division)|Consulting Fee-AURINIA PHARMA U.S., INC.|Grant or research support-BRISTOL-MYERS SQUIBB|Grant or research support-CRISPR Therapeutics|Consulting Fee-Exagen Diagnostics|Consulting Fee-GENENTECH (Relationship has ended)|Consulting Fee-GLAXOSMITHKLINE|Consulting Fee-Hinge Bio (Relationship has ended)|Consulting Fee-Invivyd|Consulting Fee-Kymera Therapeutics (Relationship has ended)|Consulting Fee-Kypha|Royalties or Patent Beneficiary-Kypha|Consulting Fee-Miltenyi Biomedicine (Relationship has ended)|Grant or research support-NOVARTIS PHARMACEUTICALS|Honoraria-The Rheumatology Education Group|Honoraria-UpToDate|Consulting Fee-Zenas BioPharma

Brad Rovin, MD, FASN, FACP
Professor of Medicine
Ohio State University Wexner Medical Center
Columbus, OH

Faculty

Ladan Zand, MD
Program Director to Glomerular Diseases Fellowship
Mayo Clinic
Rochester, MN

Faculty

Nidia Messias, MD
Professor, Pathology & Immunology
Washington University in St. Louis
St. Louis, MO

Other Planning Committee Member

Other relevant financial or material interests-Novartis (*)

Reena Gurung, MD
Assistant Professor of Medicine
Washington University in St. Louis
St. Louis, MO

Peer Reviewer

Nothing to disclose